Clinical Trials
3 trialsNCT02688712 2026-04-13
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Providence Health & Services
Phase 2 Active not recruiting
NCT02452008 2025-12-19
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT01582269 2025-11-24
A Study in Recurrent Glioblastoma (GB)
Eli Lilly and Company
Phase 2 Completed